In the context of aging and AD, despite the complexity and mixed evidence reported for both up- and downregulation of the VEGF-A gene and protein expression in the brain, fluid cerebrospinal and blood [56], there is increasing evidence that the VEGF-A gene plays a critical role in reducing glucose uptake [57], with neuroprotective effects or even represents, according to some authors, a potential biomarker of neuroinflammation [58]. Here, VEGFA is linked to Alzheimer disease.